Polyphor awarded $3 million to advance POL6014 in CF
23 March 2016 | By Victoria White
Polyphor's POL6014 reduces the activity of elastase, an enzyme that destroys lung tissue when it is produced in excess...
List view / Grid view
News
Rising sun: generic consumption accelerating at CPhI Japan
23 March 2016 | By CPhI
CPhI Japan, organised by UBM EMEA, will take place at the Big Sight Exhibition Centre, Tokyo, Japan, 20th-22nd April...
Wickham Labs to Present at BioTrinity 2016
23 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will be presenting as part of the biotech track at the 10th annual BioTrinity 2016 conference in London, April 25-27...
NICE says ‘no’ to cystic fibrosis drug Orkambi in draft guidance
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
Brilinta misses primary endpoint in SOCRATES trial
23 March 2016 | By Victoria White
The SOCRATES trial evaluated Brilinta (ticagrelor) versus aspirin for the prevention of major vascular events in patients with an acute ischaemic stroke...
FDA approves Lilly’s Taltz for plaque psoriasis
23 March 2016 | By Victoria White
Taltz (ixekizumab) is intended for adult patients who are candidates for systemic therapy, phototherapy or a combination of both...
Positive results for Praluent in patients undergoing LDL apheresis therapy
23 March 2016 | By Victoria White
Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo....
Phase III study of tivantinib in hepatocellular carcinoma continues
22 March 2016 | By Victoria White
ArQule and Daiichi Sankyo today announced that the independent DMC has determined that the METIV-HCC will continue to its final analysis...
Cherwell introduces new Redipor® prepared media products to support customer needs
22 March 2016 | By Cherwell Laboratories
New 2016 Redipor® price list available on request...
Moberg Pharma announces plans to develop BUPI into Phase III
22 March 2016 | By Victoria White
BUPI is a patent pending lozenge formulation of bupivacaine for pain management in oral mucositis in cancer patients...
Daratumumab and atezolizumab to be evaluated in two studies
22 March 2016 | By Victoria White
The studies will assess the combination of daratumumab and atezolizumab in multiple myeloma and in solid tumour cancer...
Pharmapack Europe integral to anti-counterfeiting efforts
22 March 2016 | By Victoria White
Pharmapack Europe, organised by UBM EMEA, held its most successful event yet at the Paris expo Porte De Versailles on the 10th and 11th of February 2016...
Pfizer announces results from studies of tofacitinib in ulcerative colitis
21 March 2016 | By Victoria White
Results from OCTAVE Induction 1 and 2, evaluating the efficacy and safety of oral tofacitinib in inducing remission in ulcerative colitis, were presented at ECCO...
MSD presents data from Simponi GO-COLITIS trial
21 March 2016 | By Victoria White
GO-COLITIS evaluated the efficacy of Simponi (golimumab) in inducing and maintaining clinical response in patients with moderate to severe ulcerative colitis...
NICE recommends abiraterone for some prostate cancer patients
21 March 2016 | By Victoria White
Professor Paul Workman of The Institute of Cancer Research, which discovered abiraterone, said the recommendation was “a big victory for men"...
